dacarbazine and Central Nervous System Neoplasm

dacarbazine has been researched along with Central Nervous System Neoplasm in 107 studies

Research

Studies (107)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (0.93)	18.2507
2000's	46 (42.99)	29.6817
2010's	57 (53.27)	24.3611
2020's	3 (2.80)	2.80

Authors

Authors	Studies
Fu, C; Shang, J; Wu, D; Yan, L; Yao, W; Zhai, Y	1
Badgett, T; Crimella, J; Fridley, BL; Gill, J; Gorlick, R; Llosa, N; Metts, JL; Reed, D; Sandler, E; Sansil, S; Smith, T; Thapa, R; Thompson, P; Trucco, M; Weiser, DA	1
Carrillo, JA; Gill, JM; Kesari, S; Nguyen, M; Sharma, A; Truong, J; Wagle, N; Yalamanchi, M	1
Costa, B; Da Settimo, F; Daniele, S; Giacomelli, C; Giustiniano, M; La Pietra, V; La Regina, G; Marinelli, L; Martini, C; Novellino, E; Pietrobono, D; Silvestri, R; Taliani, S; Trincavelli, ML	1
Armand, P; Batchelor, TT; Chen, YB; DeFilipp, Z; El-Jawahri, A; Li, S; Nayak, L; Wang, N	1
Jin, J; Mao, L; Wang, H; Wang, L; Wang, M; Wei, J	1
Liu, F; Wang, C; Zheng, J	1
Botti, A; Cagni, E; Ciammella, P; D'Abbiero, N; Galeandro, M; Iori, M; Iotti, C; Pisanello, A; Podgornii, A	1
Austin, AD; Desjardins, A; Friedman, HS; Herndon, JE; Jiang, X; McLendon, RE; Quinn, JA; Reardon, DA; Vredenburgh, JJ	1
Shi, L; Sun, G; Wan, Y; Wang, Z; Zeng, Y; Zhang, S	1
Bachour, M; Hussein, T; Kenj, M; Salamoon, M	1
Balañá, C; Gallego, O; García, JL; Iglesias, L; Pérez, P; Reynés, G	1
Lin, ZX; Yang, LJ; Zhou, CF	1
Debatin, KM; Dwucet, A; Halatsch, ME; Karpel-Massler, G; Kast, RE; Nonnenmacher, L; Westhoff, MA; Wirtz, CR	1
Bakó, G; Barzó, P; Bognár, L; Daróczi, B; Hideghéty, K; Mózes, P; Szántó, E; Szántó, J; Tóth, J	1
Bai, B; Cai, QC; Cai, QQ; Gao, Y; Huang, HQ; Jiang, WQ; Wang, XX; Xia, YF; Xia, ZJ	1
Fuentes-Raspall, R; Guerra-Prio, S; Marcos-Gragera, R; Perez-Bueno, F; Puig-Vives, M	1
Canal, F; Cavallin, S; Dei Tos, AP; Gherlinzoni, F; Scarpa, M; Scquizzato, E; Stefani, PM; Toffolatti, L	1
Bersvendsen, H; Eriksson, M; Erlanson, M; Fagerli, UM; Fiirgaard, B; Fluge, Ø; Fosså, A; Hagberg, H; Kuittinen, O; Leppä, S; Nordstrøm, M; Pulczynski, EJ; Østenstad, B	1
Agaimy, A; Kloska, S; Linker, RA; Olmes, DG	1
Du, S; Liao, G; Ren, C; Sun, H; Xie, X; Yuan, YW	1
Burrows, SH; Mannari, D	1
Barrié, M; Benouaich-Amiel, A; Chinot, O; Choquet, S; del Rio, MS; Delgadillo, D; Delwail, V; Ghesquieres, H; Gonzalez-Aguilar, A; Gressin, R; Gyan, E; Hoang-Xuan, K; Houillier, C; Huchet, A; Lacomblez, L; Lamy, T; Lebouvier-Sadot, S; Omuro, A; Soubeyran, P; Soussain, C; Taillandier, L; Tanguy, ML; Touitou, V	1
Ackland, S; Back, M; Buyse, ME; Kerestes, Z; Khasraw, M; Kichenadasse, G; Lee, A; McCowatt, S; Wheeler, H	1
Augspurger, M; Bartlett, NL; Bokstein, F; Bovi, JA; Brat, D; Fisher, BJ; Glass, J; Liepman, MK; Mehta, MP; Schultz, CJ; Solhjem, MC; Suh, JH; Werner-Wasik, M; Won, M	1
Bodaghi, B; Cassoux, N; Choquet, S; Costopoulos, M; Hoang-Xuan, K; Houillier, C; Le Cossec, C; Legarf-Tavernier, M; LeHoang, P; Nguyen, DT; Omuro, A; Soussain, C; Touitou, V	1
Chen, BD; Chen, L; Li, QZ; Li, WP; Li, ZY; Wang, B; Zhang, XJ	1
Hertenstein, A; Platten, M; Wick, W	1
Belka, C; Eigenbrod, S; Kreth, FW; Kreth, S; Lutz, J; Niyazi, M; Schüller, U; Thon, N; Thorsteinsdottir, J; Tonn, JC	1
Ceylan, S; Gokturk, D; Kelebek, H; Yilmaz, DM	1
Back, M; Baumert, BG; Brandes, AA; Cairncross, JG; Chinot, O; Ding, K; Fariselli, L; Fay, M; Feuvret, L; Franceschi, E; Golfinopoulos, V; Hirte, H; Laigle-Donadey, F; Laperriere, N; Mason, WP; Menten, J; Nishikawa, R; O'Callaghan, CJ; Osoba, D; Perry, JR; Phillips, C; Roa, W; Rossiter, JP; Sahgal, A; Tills, M; Wick, A; Wick, W; Winch, C	1
Adumala, RR; Altaha, R; Crowell, EB; Hobbs, GR; Vinjamuri, M	1
Andrews, D; Curran, WJ; Dicker, AP; Kubicek, GJ; Machtay, M; Mallon, G; Myers, T; Ramirez, M; Werner-Wasik, M	1
Annibali, O; Avvisati, G; Cellini, F; Greco, R; Nobile, C; Petrucci, MT; Quattrocchi, CC; Tirindelli, MC	1
Lesser, GJ; Ruiz, J	1
Baumert, BG; Leffers, P; Tjon-A-Fat, H; Twijnstra, A; van Genugten, JA	1
Abutarif, MA; Cantillon, M; Cutler, D; Diez, BD; Kantesaria, B; Ottaviano, FH; Pallotta, MG; Schwarz, M; Statkevich, P; Xuan, F; Zhu, Y	1
Beier, CP; Beier, D; Bogdahn, U; Brawanski, A; Dietmaier, C; Gorlia, T; Grauer, O; Hau, P; Hegi, M; Hirschmann, B; Jauch-Worley, T; Kleinletzenberger, C; Kölbl, O; Muigg, A; Pietsch, T; Proescholdt, M; Rümmele, P; Schmid, C; Steinbrecher, A; Stockhammer, G	1
Murawski, N; Pfreundschuh, M	1
Glas, M; Herrlinger, U; Kurzwelly, D; Lohner, H; Reifenberger, G; Roth, P; Schabet, M; Waha, A; Weimann, E; Weller, M	1
Yamanaka, R	1
Park, DM; Rich, JN; Sathornsumetee, S	1
Freyschlag, CF; Nölte, I; Pechlivanis, I; Schmieder, K; Seiz, M; Tuettenberg, J; Vajkoczy, P	1
Aird, E; Bar-Deroma, R; Baumert, BG; Bernard Davis, J; Collette, L; Fenton, P; Gulyban, A; Musat, E; Roelofs, E; Stupp, R; Weber, DC	1
Aguado, JM; García-Reyne, A; Juan, RS; Lalueza, A; Lizasoain, M; López-Medrano, F; Martínez, P; Meije, Y; Rodríguez, V	1
Abacioglu, U; Akgun, Z; Atasoy, BM; Caglar, HB; Sengoz, M; Yumuk, PF	1
Boddy, AV; Castelbuono, DJ; Clifford, SC; Curtin, NJ; Daniel, RA; Drew, Y; Hostomsky, Z; Mulligan, EA; Plummer, ER; Rozanska, AL; Thomas, HD; Tweddle, DA	1
Aoki, T; Fujimaki, T; Itoh, K; Kajiwara, K; Kurisu, K; Mineta, T; Narita, Y; Sawamura, Y; Shibui, S; Terasaki, M; Yamada, A	1
Adair, J; Kiem, HP; Mrugala, MM	1
Bangert, A; Cristofanon, S; Debatin, KM; Fulda, S; Häcker, S	1
Hide, T; Kuratsu, J; Makino, K; Nakamura, H	1
Adachi, J; Fukuoka, K; Matsutani, M; Mishima, K; Nishikawa, R; Sasaki, A; Suzuki, T; Wakiya, K; Yanagisawa, T	1
Ahluwalia, MS	1
Asano, S; Fujimaki, T; Hoya, K; Ishida, Y; Matsuno, A; Murakami, M; Nakaguchi, H; Yamada, SM; Yamazaki, K	1
Bradshaw, TD; Stevens, MF; Zhang, J	1
Behler, CM; Cha, S; Damon, LE; Hwang, J; Issa, S; McDermott, M; O'Brien, J; Rubenstein, JL; Shuman, MA; Treseler, P; Valles, F; Wieduwilt, MJ	1
Anelli, V; Bassi, R; Brioschi, L; Campanella, R; Caroli, M; De Zen, F; Gaini, SM; Giussani, P; Riboni, L; Riccitelli, E; Viani, P	1
Falchi, L; Ferranti, L; Gunnellini, M; Liberati, AM	1
Itoh, T; Kimura, T; Kohsaka, S; Mahabir, R; Narita, T; Nishihara, H; Tanaka, S; Tanino, M; Wang, L; Yachi, K	1
Andrés, R; Balañá, C; Benavides, M; de Las Peñas, R; Fernández-Chacón, C; Gallego, O; García-Velasco, A; Gil, MJ; Herrero, A; Martínez-García, M; Mesia, C; Pérez-Martin, X; Peréz-Segura, P; Quintanar, T; Reynés, G	1
Abrey, LE; Deangelis, LM; Drappatz, J; Gilbert, MR; Nayak, L; Omuro, A; Prados, M; Reardon, DA; Wen, PY	1
Codacci-Pisanelli, G; Della Rocca, C; Frati, L; Gulino, A; Lo Russo, G; Miele, E; Miscusi, M; Papa, A; Petrozza, V; Spinelli, GP; Tomao, S	1
Matsko, MV	1
Aguilar, LK; Aguilar-Cordova, E; Arvizu, M; Chiocca, EA	1
Masood, N; Osmani, AH	1
Bao, Z; Chen, CC; Jiang, C; Jiang, T; Kang, C; Li, S; Song, SW; Yan, W; You, G; You, Y; Zhang, J; Zhang, W; Zhang, Y	1
Cher, L; Gan, HK; Wong, SF	1
Nieder, C	2
Beauchesne, P	1
Bigner, DD; Colvin, OM; Dolan, ME; Friedman, HS; Houghton, PJ; Keir, S; Moschel, RC; Pegg, AE	1
Basso, U; Berti, F; Brandes, AA; Ermani, M; Gardiman, M; Monfardini, S; Pinna, G; Rotilio, A; Scienza, R; Vastola, F	1
Ames, P; Boasberg, PD; Deck, R; Kristedja, TS; Martin, M; O'Day, SJ; Petrovich, Z; Shinn, K; Tamar, B; Wang, H	1
Maltoni, S; Messori, A; Pelagotti, F; Trippoli, S; Vacca, F; Vaiani, M	1
Dolan, ME; Nagasubramanian, R	1
Buster, WP; Gruber, ML	1
Benítez, E; Gil-Salú, JL; López-Escobar, M; Maestro, E; Pérez-Requena, J; Román, P	1
Fazeny-Dörner, B; Mader, RM; Marosi, C; Piribauer, M; Rizovski, B; Stögermaier, B	1
Barron, L; Tishler, R; Wong, ET; Wu, JK	1
Abrey, LE; DeAngelis, LM; Demopoulos, A; Enting, RH	1
Arrigo, C; Pitini, V; Righi, M	1
Alemu, C; Calvin, D; Graziani, G; Hoover, R; Lapidus, R; Leonetti, C; Morgan, L; Scarsella, M; Tang, Z; Tentori, L; Vergati, M; Woznizk, K; Xu, W; Zhang, J	1
Freeman, BB; Gajjar, A; Iacono, LC; Kirstein, MN; Nair, G; Panetta, JC; Stewart, CF	1
Geddis, A; Kadota, R; Kerlin, B; Kung, F; Levy, M; Loh, KC; Martin, L; Meltzer, H; Roberts, W; Schiff, D; Spear, MA; White, G; Willert, J; Yu, A	1
Dichgans, J; Hebart, H; Herrlinger, U; Kanz, L; Weller, M	1
Chiusolo, P; De Matteis, S; De Vita, S; Fiorini, A; Laurenti, L; Leone, G; Reddiconto, G; Sica, S	1
Reardon, DA	1
Blatt, V; Brandes, AA; Cavallo, G; Ermani, M; Franceschi, E; Gardiman, M; Ghimenton, C; Pasetto, L; Scopece, L; Tosoni, A	1
Bigner, DD; Friedman, HS; Reardon, DA; Rich, JN	1
Gagua, RO; Ninua, NG; Papuashvili, GSh	1
Wong, ET	1
Kawaguchi, T; Mirzoeva, OK; Pieper, RO	1
Aristu, J; De la Cruz, S; Fernández Hidalgo, O; Nieto, Y; Santisteban, M; Zubieta, JL	1
Bernstein, M; Fort, D; Friedman, H; Harris, MB; Kadota, R; Krailo, M; Kretschmar, CS; Mazewski, C; Nicholson, HS; Reaman, GH; Sato, J; Tedeschi-Blok, N	1
Barrie, M; Carnin, C; Chinot, O; Hoang-Xuan, K; Omuro, AM; Taillandier, L	1
Kobayashi, K; Nagane, M; Ohnishi, A; Shimizu, S; Shiokawa, Y	1
Bredel, M	1
Bigner, DD; Catino, JJ; Dolan, ME; Friedman, HS; Keir, S; Marcelli, S; Pegg, AE; Schold, SC	1
Atkins, MB; Clancy, MA; Lawrence, DP; McDermott, DF; Mier, JW; Rubin, KM; van den Brink, MR	1
Brandes, AA; Monfardini, S; Pasetto, LM; Vastola, F	1
Macdonald, DR	1
Chinot, O	1
Newlands, E; Stupp, R	1
Prados, M	1
Yung, WK	1
Bonmassar, E; d'Amati, G; Graziani, G; Leonetti, C; Portarena, I; Scarsella, M; Tentori, L; Zupi, G	1
Dichgans, J; Herrlinger, U; Küker, W; Platten, M; Weller, M	1

Reviews

17 review(s) available for dacarbazine and Central Nervous System Neoplasm

Article	Year
Temozolomide and radiotherapy for newly diagnosed glioblastoma multiforme: a systematic review. Cancer investigation, 2014, Volume: 32, Issue:2 Topics: Antineoplastic Agents, Alkylating; Central Nervous System Neoplasms; Chemoradiotherapy; Dacarbazine; Disease-Free Survival; Glioblastoma; Humans; Temozolomide	2014
Do glioma patients derive any therapeutic benefit from taking a higher cumulative dose of temozolomide regimens?: a meta-analysis. Medicine, 2015, Volume: 94, Issue:20 Topics: Antineoplastic Agents, Alkylating; Central Nervous System Neoplasms; Dacarbazine; Glioma; Humans; Temozolomide; Treatment Outcome	2015
Low-grade gliomas. Current treatment options in oncology, 2009, Volume: 10, Issue:3-4 Topics: Adult; Aged; Central Nervous System Neoplasms; Chromosome Mapping; Clinical Trials as Topic; Dacarbazine; Disease-Free Survival; Glioma; Humans; Medical Oncology; Middle Aged; Prognosis; Temozolomide; Treatment Outcome	2009
[Medical management of primary central nervous system lymphoma refractory or resistant to standard of care treatment]. Brain and nerve = Shinkei kenkyu no shinpo, 2009, Volume: 61, Issue:10 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Combined Modality Therapy; Dacarbazine; Drug Discovery; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Methotrexate; Neoplasm Recurrence, Local; Rituximab; Salvage Therapy; Temozolomide; Topotecan	2009
Emergence of cytomegalovirus disease in patients receiving temozolomide: report of two cases and literature review. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2010, Jun-15, Volume: 50, Issue:12 Topics: Aged; Antineoplastic Agents, Alkylating; Central Nervous System Neoplasms; Cytomegalovirus Infections; Dacarbazine; Female; Glioblastoma; Humans; Lymphoma, B-Cell; Male; Middle Aged; Opportunistic Infections; Temozolomide	2010
Temozolomide: Expanding its role in brain cancer. Drugs of today (Barcelona, Spain : 1998), 2010, Volume: 46, Issue:11 Topics: Aged; Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Central Nervous System Neoplasms; Dacarbazine; Drug Resistance, Neoplasm; Glioma; Humans; Temozolomide	2010
Chemotherapy and target therapy in the management of adult high- grade gliomas. Current cancer drug targets, 2012, Volume: 12, Issue:8 Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Central Nervous System Neoplasms; Cetuximab; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; ErbB Receptors; Erlotinib Hydrochloride; Glioma; Humans; Nitrosourea Compounds; Organophosphorus Compounds; Promoter Regions, Genetic; Quinazolines; Temozolomide; TOR Serine-Threonine Kinases; Tumor Suppressor Proteins	2012
The spectrum of vaccine therapies for patients with glioblastoma multiforme. Current treatment options in oncology, 2012, Volume: 13, Issue:4 Topics: Acyclovir; Autoantigens; Central Nervous System Neoplasms; Combined Modality Therapy; Dacarbazine; Dendritic Cells; Glioblastoma; Humans; Immunotherapy; Immunotherapy, Active; Signal Transduction; Temozolomide; Valacyclovir; Valine	2012
Temozolomide: realizing the promise and potential. Current opinion in oncology, 2003, Volume: 15, Issue:6 Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Central Nervous System Neoplasms; Dacarbazine; Drug Administration Schedule; Drug Resistance, Neoplasm; Glioma; Humans; Temozolomide	2003
Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide. Neurology, 2004, Sep-14, Volume: 63, Issue:5 Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antigens, Neoplasm; Antineoplastic Agents, Alkylating; Brain Neoplasms; Central Nervous System Neoplasms; Cohort Studies; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Drug Evaluation; Drug Resistance, Neoplasm; Eye Neoplasms; Female; Humans; Immunotherapy; Life Tables; Lymphoma, B-Cell; Male; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Remission Induction; Retrospective Studies; Rituximab; Salvage Therapy; Survival Analysis; Temozolomide; Treatment Outcome	2004
Recent advances in the treatment of malignant astrocytoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Mar-10, Volume: 24, Issue:8 Topics: Antineoplastic Agents; Astrocytoma; Central Nervous System Neoplasms; Combined Modality Therapy; Dacarbazine; DNA Methylation; Humans; Temozolomide	2006
Temozolomide in patients with high grade gliomas. Oncology, 2000, Volume: 59, Issue:3 Topics: Antineoplastic Agents, Alkylating; Central Nervous System Neoplasms; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Dacarbazine; Glioma; Humans; Temozolomide	2000
Temozolomide for recurrent high-grade glioma. Seminars in oncology, 2001, Volume: 28, Issue:4 Suppl 13 Topics: Antineoplastic Agents, Alkylating; Astrocytoma; Central Nervous System Neoplasms; Clinical Trials as Topic; Dacarbazine; Glioblastoma; Glioma; Humans; Quality of Life; Temozolomide	2001
Chemotherapy for the treatment of oligodendroglial tumors. Seminars in oncology, 2001, Volume: 28, Issue:4 Suppl 13 Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Clinical Trials as Topic; Dacarbazine; Humans; Lomustine; Oligodendroglioma; Procarbazine; Prognosis; Temozolomide; Vincristine	2001
New approaches for temozolomide therapy: use in newly diagnosed glioma. Seminars in oncology, 2001, Volume: 28, Issue:4 Suppl 13 Topics: Antineoplastic Agents, Alkylating; Central Nervous System Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Dacarbazine; Drug Administration Schedule; Glioma; Humans; Quality of Life; Temozolomide	2001
Temozolomide in combination with other cytotoxic agents. Seminars in oncology, 2001, Volume: 28, Issue:4 Suppl 13 Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carmustine; Central Nervous System Neoplasms; Clinical Trials as Topic; Dacarbazine; Drug Implants; Glioma; Humans; Irinotecan; Temozolomide	2001
Future directions for temozolomide therapy. Seminars in oncology, 2001, Volume: 28, Issue:4 Suppl 13 Topics: Antineoplastic Agents, Alkylating; Central Nervous System Neoplasms; Clinical Trials as Topic; Dacarbazine; Drug Administration Schedule; Drug Resistance, Neoplasm; Forecasting; Humans; Temozolomide	2001

Trials

28 trial(s) available for dacarbazine and Central Nervous System Neoplasm

Article	Year
A phase I trial of metformin in combination with vincristine, irinotecan, and temozolomide in children with relapsed or refractory solid and central nervous system tumors: A report from the national pediatric cancer foundation. Cancer medicine, 2023, Volume: 12, Issue:4 Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Central Nervous System Neoplasms; Child; Child, Preschool; Dacarbazine; Humans; Irinotecan; Maximum Tolerated Dose; Metformin; Neoplasm Recurrence, Local; Neoplasms; Sarcoma, Ewing; Temozolomide; Vincristine	2023
O6-methylguanine-DNA methyltransferase (MGMT) immunohistochemistry as a predictor of resistance to temozolomide in primary CNS lymphoma. Journal of neuro-oncology, 2013, Volume: 114, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Central Nervous System Neoplasms; Dacarbazine; Drug Resistance, Neoplasm; Female; Humans; Longitudinal Studies; Lymphoma; Male; Middle Aged; O(6)-Methylguanine-DNA Methyltransferase; Retrospective Studies; Temozolomide	2013
A phase I study of irinotecan in combination with metronomic temozolomide in patients with recurrent glioblastoma. Anti-cancer drugs, 2014, Volume: 25, Issue:6 Topics: Administration, Metronomic; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Central Nervous System Neoplasms; Dacarbazine; Female; Glioblastoma; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Temozolomide	2014
Successful change of treatment strategy in elderly patients with primary central nervous system lymphoma by de-escalating induction and introducing temozolomide maintenance: results from a phase II study by the Nordic Lymphoma Group. Haematologica, 2015, Volume: 100, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Dacarbazine; Female; Follow-Up Studies; Humans; Lymphoma, Non-Hodgkin; Maintenance Chemotherapy; Male; Middle Aged; Neoplasm Staging; Remission Induction; Survival Analysis; Temozolomide; Treatment Outcome	2015
Methotrexate and temozolomide versus methotrexate, procarbazine, vincristine, and cytarabine for primary CNS lymphoma in an elderly population: an intergroup ANOCEF-GOELAMS randomised phase 2 trial. The Lancet. Haematology, 2015, Volume: 2, Issue:6 Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Cytarabine; Dacarbazine; Disease-Free Survival; Female; Humans; Lymphoma; Male; Methotrexate; Middle Aged; Procarbazine; Prospective Studies; Quality of Life; Temozolomide; Treatment Outcome; Vincristine	2015
Cilengitide with metronomic temozolomide, procarbazine, and standard radiotherapy in patients with glioblastoma and unmethylated MGMT gene promoter in ExCentric, an open-label phase II trial. Journal of neuro-oncology, 2016, Volume: 128, Issue:1 Topics: Adult; Aged; Antineoplastic Agents; Central Nervous System Neoplasms; Chemoradiotherapy; Dacarbazine; Disease Progression; Disease-Free Survival; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Drug Therapy, Combination; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Procarbazine; Snake Venoms; Temozolomide; Treatment Failure; Tumor Suppressor Proteins; Young Adult	2016
Phase I and II Study of Induction Chemotherapy With Methotrexate, Rituximab, and Temozolomide, Followed By Whole-Brain Radiotherapy and Postirradiation Temozolomide for Primary CNS Lymphoma: NRG Oncology RTOG 0227. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016, 05-10, Volume: 34, Issue:14 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Chemoradiotherapy; Dacarbazine; Disease-Free Survival; Female; Humans; Induction Chemotherapy; Lymphoma; Male; Methotrexate; Middle Aged; Rituximab; Temozolomide; Whole-Body Irradiation; Young Adult	2016
Primary Oculocerebral Lymphoma: MTX Polychemotherapy Alone on Intraocular Disease Control. Ophthalmology, 2016, Volume: 123, Issue:9 Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Cerebellum; Cytarabine; Dacarbazine; Eye Neoplasms; Female; Humans; Lymphoma; Magnetic Resonance Imaging; Male; Methotrexate; Middle Aged; Procarbazine; Survival Analysis; Temozolomide; Vincristine	2016
Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma. The New England journal of medicine, 2017, 03-16, Volume: 376, Issue:11 Topics: Aged; Aged, 80 and over; Central Nervous System Neoplasms; Chemoradiotherapy; Dacarbazine; Disease Progression; Female; Glioblastoma; Humans; Male; Quality of Life; Radiotherapy; Survival Analysis; Temozolomide	2017
Comparative analysis of temozolomide (TMZ) versus 1,3-bis (2-chloroethyl)-1 nitrosourea (BCNU) in newly diagnosed glioblastoma multiforme (GBM) patients. Journal of neuro-oncology, 2009, Volume: 91, Issue:2 Topics: Antineoplastic Agents, Alkylating; Carmustine; Central Nervous System Neoplasms; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Female; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Staging; Radiotherapy; Retrospective Studies; Salvage Therapy; Temozolomide; Treatment Outcome	2009
Phase I trial using proteasome inhibitor bortezomib and concurrent temozolomide and radiotherapy for central nervous system malignancies. International journal of radiation oncology, biology, physics, 2009, Jun-01, Volume: 74, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Boronic Acids; Bortezomib; Central Nervous System Neoplasms; Dacarbazine; Drug Administration Schedule; Female; Glioblastoma; Humans; Male; Middle Aged; Pyrazines; Radiotherapy; Temozolomide; Treatment Outcome	2009
Effectiveness of temozolomide for primary glioblastoma multiforme in routine clinical practice. Journal of neuro-oncology, 2010, Volume: 96, Issue:2 Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Central Nervous System Neoplasms; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Female; Follow-Up Studies; Glioblastoma; Humans; Male; Middle Aged; Radiotherapy; Retrospective Studies; Temozolomide; Time Factors; Treatment Outcome	2010
Evaluation of the exposure equivalence of oral versus intravenous temozolomide. Cancer chemotherapy and pharmacology, 2010, Volume: 65, Issue:4 Topics: Administration, Oral; Adult; Anemia; Antineoplastic Agents, Alkylating; Area Under Curve; Central Nervous System Neoplasms; Constipation; Cross-Over Studies; Dacarbazine; Drug Administration Schedule; Female; Headache; Humans; Infusions, Intravenous; Male; Metabolic Clearance Rate; Middle Aged; Nausea; Temozolomide; Therapeutic Equivalency; Time Factors; Vomiting	2010
RNOP-09: pegylated liposomal doxorubicine and prolonged temozolomide in addition to radiotherapy in newly diagnosed glioblastoma--a phase II study. BMC cancer, 2009, Sep-02, Volume: 9 Topics: Adolescent; Adult; Aged; Central Nervous System Neoplasms; Combined Modality Therapy; Dacarbazine; Doxorubicin; Drug Administration Schedule; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Glioblastoma; Humans; Male; Middle Aged; Polyethylene Glycols; Temozolomide; Young Adult	2009
Efficacy of protracted dose-dense temozolomide in patients with recurrent high-grade glioma. Journal of neuro-oncology, 2011, Volume: 103, Issue:3 Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Central Nervous System Neoplasms; Dacarbazine; Disease-Free Survival; Drug Administration Schedule; Female; Follow-Up Studies; Glioma; Humans; Male; Middle Aged; Retrospective Studies; Temozolomide; Treatment Outcome; Young Adult	2011
Phase I trial of a personalized peptide vaccine for patients positive for human leukocyte antigen--A24 with recurrent or progressive glioblastoma multiforme. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, Jan-20, Volume: 29, Issue:3 Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Cancer Vaccines; Central Nervous System Neoplasms; Dacarbazine; Dose-Response Relationship, Immunologic; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Glioblastoma; HLA-A Antigens; HLA-A24 Antigen; Humans; Japan; Male; Middle Aged; Precision Medicine; Recurrence; Survival Analysis; T-Lymphocytes, Cytotoxic; Temozolomide; Vaccines, Subunit	2011
Immunochemotherapy with intensive consolidation for primary CNS lymphoma: a pilot study and prognostic assessment by diffusion-weighted MRI. Clinical cancer research : an official journal of the American Association for Cancer Research, 2012, Feb-15, Volume: 18, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Brain; Central Nervous System Neoplasms; Consolidation Chemotherapy; Cytarabine; Dacarbazine; Diffusion Magnetic Resonance Imaging; Etoposide; Female; Humans; Immunotherapy; Lymphoma; Male; Methotrexate; Middle Aged; Prognosis; Remission Induction; Rituximab; Survival Analysis; Temozolomide; Treatment Outcome	2012
Multicenter phase II study of rituximab and temozolomide in recurrent primary central nervous system lymphoma. Leukemia & lymphoma, 2013, Volume: 54, Issue:1 Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Brain; Central Nervous System Neoplasms; Dacarbazine; Female; Humans; Lymphoma; Magnetic Resonance Imaging; Male; Middle Aged; Recurrence; Rituximab; Salvage Therapy; Temozolomide; Treatment Outcome	2013
A prospective study on glioblastoma in the elderly. Cancer, 2003, Feb-01, Volume: 97, Issue:3 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Combined Modality Therapy; Dacarbazine; Female; Glioblastoma; Humans; Lomustine; Male; Neurosurgical Procedures; Procarbazine; Prospective Studies; Radiotherapy Dosage; Survival Analysis; Temozolomide; Vincristine	2003
Biochemotherapy for metastatic melanoma with limited central nervous system involvement. Oncology, 2003, Volume: 64, Issue:4 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Cisplatin; Dacarbazine; Disease Progression; Female; Humans; Interferon alpha-2; Interferon-alpha; Interleukin-2; Male; Melanoma; Middle Aged; Neoplasm Staging; Radiosurgery; Recombinant Proteins; Survival Analysis; Treatment Outcome; Vinblastine	2003
Temozolomide in combination with irinotecan for treatment of recurrent malignant glioma. American journal of clinical oncology, 2004, Volume: 27, Issue:1 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Central Nervous System Neoplasms; Dacarbazine; Female; Glioma; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Survival Rate; Temozolomide; Treatment Outcome	2004
Preliminary study on pharmacokinetics of dacarbazine and fotemustine in glioblastoma multiforme patients does not indicate gender-specific differences. Anti-cancer drugs, 2004, Volume: 15, Issue:5 Topics: Adult; Antineoplastic Agents, Alkylating; Central Nervous System Neoplasms; Dacarbazine; Dose-Response Relationship, Drug; Female; Glioblastoma; Humans; Male; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Sex Factors	2004
Development of a pharmacokinetic limited sampling model for temozolomide and its active metabolite MTIC. Cancer chemotherapy and pharmacology, 2005, Volume: 55, Issue:5 Topics: Antineoplastic Agents, Alkylating; Area Under Curve; Central Nervous System Neoplasms; Child; Dacarbazine; Humans; Infant; Metabolic Clearance Rate; Monte Carlo Method; Temozolomide	2005
[Temozolomide--a new antitumor preparation in the treatment of central nervous system malignant tumors]. Georgian medical news, 2006, Issue:134 Topics: Antineoplastic Agents, Alkylating; Central Nervous System Neoplasms; Combined Modality Therapy; Dacarbazine; Female; Humans; Male; Temozolomide; Treatment Outcome	2006
Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group. Cancer, 2007, Oct-01, Volume: 110, Issue:7 Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Central Nervous System Neoplasms; Child; Child, Preschool; Dacarbazine; Drug Administration Schedule; Ependymoma; Female; Humans; Infant; Male; Medulloblastoma; Neoplasm Recurrence, Local; Neuroectodermal Tumors, Primitive; Temozolomide; Treatment Outcome	2007
Temozolomide and methotrexate for primary central nervous system lymphoma in the elderly. Journal of neuro-oncology, 2007, Volume: 85, Issue:2 Topics: Age Factors; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Dacarbazine; Drug Administration Schedule; Female; Humans; Lymphoma; Male; Methotrexate; Middle Aged; Retrospective Studies; Temozolomide; Treatment Outcome	2007
Nomograms as clinicobiological predictors of survival in glioblastoma. The Lancet. Oncology, 2008, Volume: 9, Issue:1 Topics: Antineoplastic Agents, Alkylating; Central Nervous System Neoplasms; Dacarbazine; Glioblastoma; Humans; Nomograms; Predictive Value of Tests; Prognosis; Temozolomide	2008
A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin 2, and interferon alpha-2B in patients with metastatic melanoma. Clinical cancer research : an official journal of the American Association for Cancer Research, 2000, Volume: 6, Issue:6 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Cisplatin; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Interferon alpha-2; Interferon-alpha; Interleukin-2; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Pilot Projects; Recombinant Proteins; Recurrence; Time Factors; Treatment Outcome; Vinblastine	2000

Other Studies

62 other study(ies) available for dacarbazine and Central Nervous System Neoplasm

Article	Year
Successful eradication of central nervous system infiltration of primary plasma cell leukemia by temozolomide. Annals of hematology, 2022, Volume: 101, Issue:11 Topics: Antineoplastic Agents, Alkylating; Central Nervous System; Central Nervous System Neoplasms; Dacarbazine; Humans; Leukemia, Plasma Cell; Temozolomide	2022
Successful and durable response of primary CNS T-cell lymphoma to upfront temozolomide monotherapy. Leukemia & lymphoma, 2021, Volume: 62, Issue:8 Topics: Central Nervous System Neoplasms; Dacarbazine; Humans; Lymphoma, T-Cell; Temozolomide	2021
Bax Activation Blocks Self-Renewal and Induces Apoptosis of Human Glioblastoma Stem Cells. ACS chemical neuroscience, 2018, 01-17, Volume: 9, Issue:1 Topics: Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Caspase 3; Caspase 7; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Central Nervous System Neoplasms; Dacarbazine; Drug Therapy, Combination; Glioblastoma; Humans; Hydrazones; Membrane Potential, Mitochondrial; Neoplastic Stem Cells; Pyrazoles; Temozolomide	2018
High-dose chemotherapy with thiotepa, busulfan, and cyclophosphamide and autologous stem cell transplantation for patients with primary central nervous system lymphoma in first complete remission. Cancer, 2017, Aug-15, Volume: 123, Issue:16 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bacterial Infections; Busulfan; Central Nervous System Neoplasms; Cyclophosphamide; Cytarabine; Dacarbazine; Disease-Free Survival; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Lymphoma; Male; Methotrexate; Middle Aged; Mucositis; Remission Induction; Retrospective Studies; Rituximab; Stem Cell Transplantation; Temozolomide; Thiotepa; Transplantation Conditioning; Transplantation, Autologous	2017
Primary central nervous system lymphoma: Retrospective analysis of 34 cases in a single centre. The Journal of international medical research, 2018, Volume: 46, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Dacarbazine; Dexamethasone; Doxorubicin; Drug Administration Schedule; Drug Dosage Calculations; Female; Humans; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Prednisone; Retrospective Studies; Rituximab; Survival Analysis; Temozolomide; Vincristine	2018
Stereotactic Brachytherapy with Iodine-125 Seeds Plus Temozolomide Induced Complete and Durable Remission in a Patient with Recurrent Primary Central Nervous System Lymphoma. World neurosurgery, 2018, Volume: 117 Topics: Antineoplastic Agents, Alkylating; Brachytherapy; Central Nervous System Neoplasms; Combined Modality Therapy; Dacarbazine; Humans; Iodine Radioisotopes; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Recurrence, Local; Neurosurgical Procedures; Radiosurgery; Remission Induction; Temozolomide	2018
Hypo-fractionated IMRT for patients with newly diagnosed glioblastoma multiforme: a 6 year single institutional experience. Clinical neurology and neurosurgery, 2013, Volume: 115, Issue:9 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Central Nervous System Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Dacarbazine; Data Interpretation, Statistical; Endpoint Determination; Female; Follow-Up Studies; Glioblastoma; Humans; Karnofsky Performance Status; Magnetic Resonance Imaging; Male; Middle Aged; Neurosurgical Procedures; Radiotherapy, Intensity-Modulated; Retrospective Studies; Survival Analysis; Temozolomide; Treatment Outcome	2013
miR-125b inhibitor may enhance the invasion-prevention activity of temozolomide in glioblastoma stem cells by targeting PIAS3. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy, 2014, Volume: 28, Issue:1 Topics: Animals; Cell Line, Tumor; Central Nervous System Neoplasms; Dacarbazine; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Mice; Mice, Nude; MicroRNAs; Molecular Chaperones; Neoplastic Stem Cells; Protein Inhibitors of Activated STAT; RNA, Small Interfering; Temozolomide	2014
High-dose methotrexate, high-dose cytarabine and temozolomide for the treatment of primary central nervous system lymphoma (PCNSL). Medical oncology (Northwood, London, England), 2013, Volume: 30, Issue:4 Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Central Nervous System Neoplasms; Cytarabine; Dacarbazine; Disease-Free Survival; Female; Humans; Male; Methotrexate; Middle Aged; Survival Rate; Temozolomide; Young Adult	2013
Artesunate enhances the antiproliferative effect of temozolomide on U87MG and A172 glioblastoma cell lines. Anti-cancer agents in medicinal chemistry, 2014, Volume: 14, Issue:2 Topics: Antineoplastic Agents; Apoptosis; Artemisinins; Artesunate; Cell Line, Tumor; Cell Proliferation; Central Nervous System Neoplasms; Dacarbazine; Drug Synergism; Glioblastoma; Humans; Inhibitory Concentration 50; Necrosis; Temozolomide	2014
Post-operative management of primary glioblastoma multiforme in patients over 60 years of age. Ideggyogyaszati szemle, 2013, Nov-30, Volume: 66, Issue:11-12 Topics: Aged; Analysis of Variance; Antineoplastic Agents, Alkylating; Central Nervous System Neoplasms; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Dacarbazine; Disease-Free Survival; Female; Glioblastoma; Humans; Hungary; Kaplan-Meier Estimate; Male; Middle Aged; Predictive Value of Tests; Prognosis; Radiotherapy, Adjuvant; Retrospective Studies; Risk Factors; Temozolomide; Treatment Outcome	2013
Clinical outcomes of patients with newly diagnosed primary central nervous system lymphoma are comparable on treatment with high-dose methotrexate plus temozolomide and with high-dose methotrexate plus cytarabine: a single-institution experience. Leukemia & lymphoma, 2014, Volume: 55, Issue:11 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Cytarabine; Dacarbazine; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Humans; Lymphoma; Male; Methotrexate; Middle Aged; Neutropenia; Remission Induction; Temozolomide; Thrombocytopenia; Treatment Outcome; Young Adult	2014
Population-based survival analyses of central nervous system tumors from 1994 to 2008. An up-dated study in the temozolomide-era. Cancer epidemiology, 2014, Volume: 38, Issue:3 Topics: Antineoplastic Agents, Alkylating; Central Nervous System Neoplasms; Dacarbazine; Female; Humans; Male; Middle Aged; Prognosis; Spain; Survival Analysis; Temozolomide	2014
MGMT promoter methylation and correlation with protein expression in primary central nervous system lymphoma. Virchows Archiv : an international journal of pathology, 2014, Volume: 465, Issue:5 Topics: Adult; Aged; Biomarkers, Tumor; Central Nervous System Neoplasms; Dacarbazine; DNA Methylation; Female; Humans; Immunohistochemistry; Lymphoma; Male; Middle Aged; O(6)-Methylguanine-DNA Methyltransferase; Promoter Regions, Genetic; Temozolomide	2014
Fatal lymphomatoid granulomatosis with primary CNS-involvement in an immunocompetent 80-year-old woman. BMJ case reports, 2014, Dec-22, Volume: 2014 Topics: Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Central Nervous System; Central Nervous System Neoplasms; Dacarbazine; Fatal Outcome; Female; Herpesvirus 4, Human; Humans; Lymphomatoid Granulomatosis; Rituximab; Temozolomide	2014
Central nervous system Hodgkin lymphoma developing during systemic chemotherapy. British journal of haematology, 2016, Volume: 172, Issue:2 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Central Nervous System Neoplasms; Dacarbazine; Disease Progression; Doxorubicin; Fatal Outcome; Hodgkin Disease; Humans; Magnetic Resonance Imaging; Male; Tomography, X-Ray Computed; Vinblastine	2016
Histone Deacetylase Inhibitor RGFP109 Overcomes Temozolomide Resistance by Blocking NF-κB-Dependent Transcription in Glioblastoma Cell Lines. Neurochemical research, 2016, Volume: 41, Issue:12 Topics: Acetylation; Active Transport, Cell Nucleus; Antineoplastic Agents, Alkylating; Apoptosis; Benzamides; Cell Cycle Proteins; Cell Line, Tumor; Cell Nucleus; Central Nervous System Neoplasms; Dacarbazine; Drug Resistance, Neoplasm; Drug Synergism; Glioblastoma; Histone Deacetylase Inhibitors; Homeodomain Proteins; Humans; NF-kappa B; Signal Transduction; Temozolomide; Transcription Factor RelA; Transcription, Genetic; Transcriptional Activation; Tumor Suppressor Proteins	2016
Highlights in Central Nervous System Tumors. JAMA oncology, 2016, Dec-01, Volume: 2, Issue:12 Topics: Aged; Aged, 80 and over; Central Nervous System Neoplasms; Clinical Trials as Topic; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Female; Glioma; Humans; Male; Temozolomide	2016
Outcome in unresectable glioblastoma: MGMT promoter methylation makes the difference. Journal of neurology, 2017, Volume: 264, Issue:2 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biopsy; Central Nervous System Neoplasms; Chemoradiotherapy; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Glioblastoma; Humans; Longitudinal Studies; Male; Middle Aged; Prognosis; Promoter Regions, Genetic; Prospective Studies; Salvage Therapy; Temozolomide; Tumor Suppressor Proteins; Young Adult	2017
The Effect of Ascorbic Acid over the Etoposide- and Temozolomide-Mediated Cytotoxicity in Glioblastoma Cell Culture: A Molecular Study. Turkish neurosurgery, 2018, Volume: 28, Issue:1 Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Ascorbic Acid; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Central Nervous System Neoplasms; Dacarbazine; DNA Damage; Drug Synergism; Etoposide; Glioblastoma; Humans; Temozolomide	2018
The combination topotecan, temozolomide and dexamethasone associated with radiotherapy as treatment of central nervous system myeloma relapse. International journal of hematology, 2009, Volume: 89, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Combined Modality Therapy; Dacarbazine; Dexamethasone; Fatal Outcome; Female; Humans; Magnetic Resonance Imaging; Middle Aged; Multiple Myeloma; Recurrence; Temozolomide; Topotecan	2009
Rituximab maintenance therapy in central nervous system lymphoma? Leukemia & lymphoma, 2009, Volume: 50, Issue:10 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Biological Availability; Central Nervous System Neoplasms; Dacarbazine; Dose-Response Relationship, Drug; Humans; Lymphoma, Large B-Cell, Diffuse; Retrospective Studies; Rituximab; Salvage Therapy; Temozolomide	2009
Primary CNS lymphoma in the elderly: temozolomide therapy and MGMT status. Journal of neuro-oncology, 2010, Volume: 97, Issue:3 Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Central Nervous System Neoplasms; Dacarbazine; Disease-Free Survival; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; Geriatrics; Humans; Lymphoma; Male; Middle Aged; Promoter Regions, Genetic; Retrospective Studies; Survival Analysis; Temozolomide; Tumor Suppressor Proteins	2010
Medical oncology: treatment and management of malignant gliomas. Nature reviews. Clinical oncology, 2010, Volume: 7, Issue:2 Topics: Angiogenesis Inhibitors; Central Nervous System Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Glioblastoma; Humans; Salvage Therapy; Temozolomide; Treatment Outcome	2010
Far-distant metastases along the CSF pathway of glioblastoma multiforme during continuous low-dose chemotherapy with temozolomide and celecoxib. Neurosurgical review, 2010, Volume: 33, Issue:3 Topics: Adult; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Celecoxib; Central Nervous System Neoplasms; Cerebrospinal Fluid; Combined Modality Therapy; Dacarbazine; Fatal Outcome; Female; Glioblastoma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Pyrazoles; Sulfonamides; Survival; Temozolomide	2010
Dummy run and conformity indices in the ongoing EORTC low-grade glioma trial 22033-26033: First evaluation of quality of radiotherapy planning. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2010, Volume: 95, Issue:2 Topics: Adult; Antineoplastic Agents, Alkylating; Central Nervous System Neoplasms; Dacarbazine; Female; Glioma; Humans; Male; Middle Aged; Neoplasm Staging; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Conformal; Temozolomide; Treatment Outcome	2010
Central nervous system penetration and enhancement of temozolomide activity in childhood medulloblastoma models by poly(ADP-ribose) polymerase inhibitor AG-014699. British journal of cancer, 2010, Nov-09, Volume: 103, Issue:10 Topics: Animals; Antineoplastic Agents, Alkylating; Cell Division; Cell Line, Tumor; Cell Survival; Central Nervous System Neoplasms; Child; Dacarbazine; DNA Mismatch Repair; DNA Repair; Humans; Indoles; Medulloblastoma; Mice; Mice, Nude; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Protein Serine-Threonine Kinases; Temozolomide; Transplantation, Heterologous	2010
Chemosensitization of glioblastoma cells by the histone deacetylase inhibitor MS275. Anti-cancer drugs, 2011, Volume: 22, Issue:6 Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Apoptosis; Benzamides; Blotting, Western; Cell Line, Tumor; Central Nervous System Neoplasms; Cisplatin; Dacarbazine; Doxorubicin; Drug Synergism; Etoposide; Glioblastoma; Histone Deacetylase Inhibitors; Histones; Humans; Microtubules; Pyridines; Temozolomide	2011
Salvage treatment with temozolomide in refractory or relapsed primary central nervous system lymphoma and assessment of the MGMT status. Journal of neuro-oncology, 2012, Volume: 106, Issue:1 Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Central Nervous System Neoplasms; Dacarbazine; Disease-Free Survival; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; Humans; Kaplan-Meier Estimate; Lymphoma; Male; Middle Aged; Salvage Therapy; Survival Analysis; Temozolomide; Tumor Suppressor Proteins	2012
O⁶-methylguanine-DNA methyltransferase promoter methylation in 45 primary central nervous system lymphomas: quantitative assessment of methylation and response to temozolomide treatment. Journal of neuro-oncology, 2012, Volume: 107, Issue:1 Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Central Nervous System Neoplasms; Dacarbazine; DNA Methylation; DNA, Neoplasm; Female; Follow-Up Studies; Humans; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Neoplasm Recurrence, Local; O(6)-Methylguanine-DNA Methyltransferase; Polymerase Chain Reaction; Promoter Regions, Genetic; Salvage Therapy; Temozolomide; Treatment Outcome	2012
American Society of Clinical Oncology 2011 CNS tumors update. Expert review of anticancer therapy, 2011, Volume: 11, Issue:10 Topics: Antineoplastic Agents; Central Nervous System Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dacarbazine; Glioblastoma; Humans; Randomized Controlled Trials as Topic; Temozolomide	2011
Combination therapy with rituximab and temozolomide for recurrent and refractory primary central nervous system lymphoma. Yonsei medical journal, 2011, Volume: 52, Issue:6 Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Central Nervous System Neoplasms; Dacarbazine; Drug Therapy, Combination; Humans; Lymphoma; Male; Middle Aged; Neoplasm Recurrence, Local; Rituximab; Temozolomide	2011
Temozolomide: mechanisms of action, repair and resistance. Current molecular pharmacology, 2012, Volume: 5, Issue:1 Topics: Antineoplastic Agents, Alkylating; Cell Line, Tumor; Central Nervous System Neoplasms; Dacarbazine; DNA Glycosylases; DNA Modification Methylases; DNA Repair; DNA Repair Enzymes; DNA-(Apurinic or Apyrimidinic Site) Lyase; Drug Resistance, Neoplasm; Glioblastoma; Guanine; Humans; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Temozolomide; Tumor Suppressor Proteins	2012
Glucosylceramide synthase protects glioblastoma cells against autophagic and apoptotic death induced by temozolomide and Paclitaxel. Cancer investigation, 2012, Volume: 30, Issue:1 Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Apoptosis; Autophagy; Cell Line, Tumor; Cell Proliferation; Cell Survival; Central Nervous System Neoplasms; Ceramides; Dacarbazine; Drug Resistance, Neoplasm; Glioblastoma; Glucosyltransferases; Humans; Paclitaxel; Temozolomide	2012
High-dose methotrexate and temozolomide associated with intrathecal liposomal cytarabine for the treatment of primary or secondary central nervous system lymphoma: a preliminary experience. Clinical neurology and neurosurgery, 2012, Volume: 114, Issue:10 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Central Nervous System Neoplasms; Cytarabine; Dacarbazine; Female; Humans; Lymphoma; Male; Methotrexate; Middle Aged; Nervous System; Temozolomide	2012
STAT3 inhibition overcomes temozolomide resistance in glioblastoma by downregulating MGMT expression. Molecular cancer therapeutics, 2012, Volume: 11, Issue:6 Topics: Antineoplastic Agents, Alkylating; Cell Line, Tumor; Central Nervous System Neoplasms; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; RNA, Small Interfering; STAT3 Transcription Factor; Temozolomide; Tumor Suppressor Proteins	2012
Bevacizumab plus irinotecan in recurrent malignant glioma shows high overall survival in a multicenter retrospective pooled series of the Spanish Neuro-Oncology Research Group (GEINO). Anti-cancer drugs, 2012, Volume: 23, Issue:6 Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Central Nervous System Neoplasms; Compassionate Use Trials; Dacarbazine; Disease Progression; Glioma; Humans; Irinotecan; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Temozolomide; Treatment Outcome	2012
[Temodal--an alkylating cytostatic agent. Effectiveness in patients with malignant gliomas]. Voprosy onkologii, 2012, Volume: 58, Issue:3 Topics: Administration, Oral; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Central Nervous System Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Doxorubicin; Drug Administration Schedule; Glioma; Humans; Irinotecan; Temozolomide	2012
Temozolomide for relapsed primary CNS lymphoma. Journal of the College of Physicians and Surgeons--Pakistan : JCPSP, 2012, Volume: 22, Issue:9 Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Dacarbazine; Humans; Lymphoma, Non-Hodgkin; Magnetic Resonance Imaging; Male; Recurrence; Salvage Therapy; Temozolomide; Treatment Outcome	2012
Whole-genome microRNA expression profiling identifies a 5-microRNA signature as a prognostic biomarker in Chinese patients with primary glioblastoma multiforme. Cancer, 2013, Feb-15, Volume: 119, Issue:4 Topics: Adult; Antineoplastic Agents, Alkylating; Asian People; Biomarkers, Tumor; Central Nervous System Neoplasms; Cohort Studies; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; Glioblastoma; Humans; Isocitrate Dehydrogenase; Male; MicroRNAs; Middle Aged; Predictive Value of Tests; Prognosis; Promoter Regions, Genetic; Reproducibility of Results; Temozolomide; Transcriptome; Tumor Suppressor Proteins	2013
A single centre study of the treatment of relapsed primary central nervous system lymphoma (PCNSL) with single agent temozolomide. Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, 2012, Volume: 19, Issue:11 Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Central Nervous System Neoplasms; Dacarbazine; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Lymphoma; Male; Middle Aged; Neoplasm Recurrence, Local; Salvage Therapy; Survival Analysis; Temozolomide	2012
Treatment of newly diagnosed glioblastoma multiforme. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Jul-15, Volume: 20, Issue:14 Topics: Antibodies, Monoclonal; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, Phase II as Topic; Dacarbazine; Glioblastoma; Humans; Meta-Analysis as Topic; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Survival Analysis; Temozolomide; Tenascin; Treatment Outcome	2002
Promising survival and concomitant radiation plus temozolomide followed by adjuvant temozolomide. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Jul-15, Volume: 20, Issue:14 Topics: Adult; Antineoplastic Agents, Alkylating; Central Nervous System Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, Phase II as Topic; Dacarbazine; Glioblastoma; Humans; Middle Aged; Prognosis; Radiotherapy, Adjuvant; Risk Factors; Survival Analysis; Temozolomide; Treatment Outcome	2002
O6-benzylguanine-mediated enhancement of chemotherapy. Molecular cancer therapeutics, 2002, Volume: 1, Issue:11 Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Camptothecin; Carmustine; Central Nervous System Neoplasms; Cyclophosphamide; Dacarbazine; DNA; Enzyme Inhibitors; Female; Guanine; Humans; Irinotecan; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Protein Synthesis Inhibitors; Temozolomide	2002
Survival of patients with recurrent malignant glioma treated with temozolomide: a retrospective observational study. Drugs in R&D, 2003, Volume: 4, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Astrocytoma; Central Nervous System Neoplasms; Clinical Trials as Topic; Dacarbazine; Female; Glioblastoma; Glioma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Oligodendroglioma; Retrospective Studies; Survival Analysis; Temozolomide; Time Factors; Treatment Outcome	2003
[Survival analysis following the addition of temozolomide to surgery and radiotherapy in patients with glioblastoma multiforme]. Neurocirugia (Asturias, Spain), 2004, Volume: 15, Issue:2 Topics: Antineoplastic Agents, Alkylating; Central Nervous System Neoplasms; Combined Modality Therapy; Dacarbazine; Glioblastoma; Humans; Middle Aged; Retrospective Studies; Survival Analysis; Survival Rate; Temozolomide; Time Factors	2004
Immunochemotherapy with rituximab and temozolomide for central nervous system lymphomas. Cancer, 2004, Jul-01, Volume: 101, Issue:1 Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Dacarbazine; Drug Synergism; Humans; Lymphoma; Middle Aged; Neoplasm Recurrence, Local; Rituximab; Temozolomide; Treatment Outcome	2004
Immunochemotherapy with rituximab and temozolomide for central nervous system lymphomas. Cancer, 2004, Dec-15, Volume: 101, Issue:12 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; Central Nervous System Neoplasms; Dacarbazine; Humans; Lymphoma; Rituximab; Temozolomide	2004
Brain distribution and efficacy as chemosensitizer of an oral formulation of PARP-1 inhibitor GPI 15427 in experimental models of CNS tumors. International journal of oncology, 2005, Volume: 26, Issue:2 Topics: Administration, Oral; Animals; Antineoplastic Agents; Area Under Curve; Biological Availability; Blood-Brain Barrier; Brain; Cell Line, Tumor; Central Nervous System Neoplasms; Chromatography, Liquid; Dacarbazine; Disease Models, Animal; Enzyme Inhibitors; Flow Cytometry; G2 Phase; Humans; Inhibitory Concentration 50; Kinetics; Mass Spectrometry; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Neoplasm Transplantation; Organic Chemicals; Poly(ADP-ribose) Polymerases; Rats; Rats, Sprague-Dawley; Temozolomide; Time Factors	2005
Temozolomide and radiation for aggressive pediatric central nervous system malignancies. Journal of pediatric hematology/oncology, 2005, Volume: 27, Issue:5 Topics: Adolescent; Antineoplastic Agents, Alkylating; Central Nervous System Neoplasms; Child; Child, Preschool; Combined Modality Therapy; Dacarbazine; Fatal Outcome; Female; Humans; Infant; Magnetic Resonance Imaging; Male; Temozolomide	2005
Relapse of primary CNS lymphoma after more than 10 years in complete remission. Journal of neurology, 2005, Volume: 252, Issue:11 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Combined Modality Therapy; Dacarbazine; Humans; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Male; Methotrexate; Neoplasm Recurrence, Local; Procarbazine; Temozolomide; Vincristine	2005
Secondary Ph+ acute lymphoblastic leukemia after temozolomide. Annals of hematology, 2005, Volume: 84, Issue:11 Topics: Adult; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Central Nervous System Neoplasms; Dacarbazine; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Pyrimidines; Temozolomide	2005
Glioblastoma--more questions than answers? Nature clinical practice. Oncology, 2006, Volume: 3, Issue:2 Topics: Antineoplastic Agents; Biomarkers, Tumor; Carmustine; Central Nervous System Neoplasms; Combined Modality Therapy; Dacarbazine; Decanoic Acids; Glioblastoma; Humans; Polyesters; Signal Transduction; Temozolomide	2006
Is protracted low-dose temozolomide feasible in glioma patients? Neurology, 2006, Feb-14, Volume: 66, Issue:3 Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Central Nervous System Neoplasms; Dacarbazine; Dose-Response Relationship, Drug; Drug Administration Schedule; Feasibility Studies; Female; Glioma; Humans; Infections; Lymphopenia; Male; Middle Aged; Temozolomide	2006
Is protracted low-dose temozolomide feasible in glioma patients? Neurology, 2006, Aug-08, Volume: 67, Issue:3 Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Central Nervous System Neoplasms; Combined Modality Therapy; Dacarbazine; Feasibility Studies; Glioma; Humans; Lymphopenia; Temozolomide	2006
The Mre11/Rad50/Nbs1 complex interacts with the mismatch repair system and contributes to temozolomide-induced G2 arrest and cytotoxicity. Molecular cancer therapeutics, 2006, Volume: 5, Issue:11 Topics: Acid Anhydride Hydrolases; Adaptor Proteins, Signal Transducing; Antineoplastic Agents, Alkylating; Carrier Proteins; Cell Cycle Proteins; Cell Line, Tumor; Central Nervous System Neoplasms; Chromatin; Dacarbazine; DNA Damage; DNA Repair; DNA Repair Enzymes; DNA-Binding Proteins; Fluorescent Antibody Technique; G2 Phase; Glioblastoma; Humans; Models, Biological; MRE11 Homologue Protein; MutL Protein Homolog 1; Nuclear Proteins; Signal Transduction; Temozolomide	2006
Primary central nervous system lymphoma treated with rituximab plus temozolomide in a second line schedule. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2007, Volume: 9, Issue:7 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Brain; Central Nervous System Neoplasms; Dacarbazine; Female; Humans; Lymphatic Irradiation; Lymphoma; Magnetic Resonance Imaging; Middle Aged; Radiography; Rituximab; Temozolomide	2007
What approach will lead to cure of glioblastoma multiforme? In regard to Barani et al. (Int J Radiat Oncol Biol Phys 2007;68:324-333) and Jones and Sanghera (Int J Radiat Oncol Biol Phys 2007;68:441-448). International journal of radiation oncology, biology, physics, 2007, Oct-01, Volume: 69, Issue:2 Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Central Nervous System Neoplasms; Dacarbazine; Glioma; Humans; Radiotherapy Dosage; Relative Biological Effectiveness; Temozolomide; Therapeutic Equivalency; Tumor Burden	2007
Prognostic significance of O6-methylguanine-DNA methyltransferase protein expression in patients with recurrent glioblastoma treated with temozolomide. Japanese journal of clinical oncology, 2007, Volume: 37, Issue:12 Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Blotting, Western; Central Nervous System Neoplasms; Child; Dacarbazine; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Nitrosourea Compounds; O(6)-Methylguanine-DNA Methyltransferase; Predictive Value of Tests; Prognosis; Temozolomide; Treatment Outcome	2007
Activity of temozolomide in the treatment of central nervous system tumor xenografts. Cancer research, 1995, Jul-01, Volume: 55, Issue:13 Topics: Animals; Carmustine; Central Nervous System Neoplasms; Dacarbazine; Female; Guanine; Humans; Male; Methyltransferases; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; O(6)-Methylguanine-DNA Methyltransferase; Procarbazine; Temozolomide; Transplantation, Heterologous	1995
Combined treatment with temozolomide and poly(ADP-ribose) polymerase inhibitor enhances survival of mice bearing hematologic malignancy at the central nervous system site. Blood, 2002, Mar-15, Volume: 99, Issue:6 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Dacarbazine; Drug Evaluation, Preclinical; Hematologic Neoplasms; Male; Mice; Mice, Inbred C57BL; Mice, Inbred DBA; Poly(ADP-ribose) Polymerase Inhibitors; Quinazolines; Survival Analysis; Survival Rate; Temozolomide	2002
First-line therapy with temozolomide induces regression of primary CNS lymphoma. Neurology, 2002, May-28, Volume: 58, Issue:10 Topics: Aged; Antineoplastic Agents, Alkylating; Central Nervous System Neoplasms; Dacarbazine; Female; Humans; Lymphoma; Male; Middle Aged; Temozolomide	2002